On May 24, 2021, LabCorp reported that nearly 87% of naturally infected COVID-19 patients maintained antibodies to SARS-CoV-2 proteins for at least 10 months, according to a new analysis of specimens from 39,086 individuals.

The study, published in The Lancet-affiliated EClinicalMedicine, offers real-world evidence of the body’s response to the virus and the possibility of protection against future infection. It is the largest known COVID-19-related study by specimen volume of its kind, harnessing Labcorp’s robust testing infrastructure to enhance the public’s understanding of this potentially deadly virus.

A team of Labcorp scientists analyzed results from tests used to detect antibodies that guard against “spike” and nucleocapsid proteins on the SARS-CoV-2 virus. Their analysis included specimens collected from 39,086 individuals with COVID-19 and tested between March 2020 and January 2021.